{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:44:29Z","timestamp":1787064269672,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ygyno.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:18:05Z","timestamp":1663118285000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy"],"prefix":"10.1016","volume":"167","author":[{"given":"Tenley R.","family":"Klc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise M.","family":"Wilhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Olawaiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Puechl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba","family":"Ali-Fehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira S.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Michael","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt K.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.09.006_bb0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.09.006_bb0010","first-page":"177","article-title":"p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis","volume":"150","author":"Tashiro","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2022.09.006_bb0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hed.20574","article-title":"Prognostic impact of HER-2\/neu expression on squamous head and neck carcinomas","volume":"29","author":"Cavalot","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.ygyno.2022.09.006_bb0025","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/ijc.26292","article-title":"Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes \u2013 a systematic review","volume":"130","author":"Chua","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.09.006_bb0030","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/GCO.0000000000000599","article-title":"Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies","volume":"32","author":"Erickson","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0040","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0045","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2022.09.006_bb0050","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0060","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0075","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0085","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2020.01.003","volume":"98","author":"Woo","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0095","doi-asserted-by":"crossref","first-page":"64431","DOI":"10.18632\/oncotarget.7043","article-title":"Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer","volume":"7","author":"de Melo","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0100","first-page":"4132","article-title":"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action","volume":"62","author":"Yakes","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0105","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Loibl","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0110","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-15-0965","article-title":"Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer","volume":"22","author":"Loibl","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0115","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0125","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.09.006_bb0130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:04:34Z","timestamp":1758773074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822005923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0090825822005923"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}